



## Financial Tear Sheet

### Corporate Profile

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).

AVEO Oncology  
Investor Relations  
Phone: 617-588-1960  
E-mail:  
[ir@aveooncology.com](mailto:ir@aveooncology.com)

### Stock Performance

#### AVEO (COMMON STOCK)

Exchange	NASDAQ (US Dollar)
Price	\$2.91
Change (%)	▼ 0.03 (1.02%)
Volume	143,420
52 Week Low	\$0.50
Market Cap	\$344,788,446
Rolling EPS	-0.74
PE Ratio	N/A

Shares Outstanding 118,321,361

Data as of 12/11/17 10:07 a.m. ET



### Recent Headlines

12/07/17

AVEO Oncology Announces Clinical Updates to Tivozanib and Ficlatusumab Programs

11/20/17

AVEO Announces Appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance

11/15/17

EUSA Pharma and AVEO Oncology Announce the First Commercial Launch of FOTIVDA® (tivozanib)

### Events

There are currently no events scheduled.

## SEC Filings

### FILING DATE FORM

11/30/17	S-3
11/30/17	S-8
11/22/17	4
11/22/17	3

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed